PE20211707A1 - Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp - Google Patents
Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrpInfo
- Publication number
- PE20211707A1 PE20211707A1 PE2021001142A PE2021001142A PE20211707A1 PE 20211707 A1 PE20211707 A1 PE 20211707A1 PE 2021001142 A PE2021001142 A PE 2021001142A PE 2021001142 A PE2021001142 A PE 2021001142A PE 20211707 A1 PE20211707 A1 PE 20211707A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- seq
- antibodies
- anticgrp
- headache
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona una composicion que comprende entre 100 mg y 300 mg de un anticuerpo anti-CGRP, que tiene las secuencias polipeptidicas de CDR 1, 2 y 3 de cadena ligera de SEQ ID NO: 224; SEQ ID NO: 226; y SEQ ID NO: 228, respectivamente y las secuencias polipeptidicas de CDR 1, 2, y 3 de cadena pesada de SEQ ID NO: 204; SEQ ID NO: 206; y SEQ ID NO: 208, respectivamente. Dichos anticuerpos proporcionan alivio de la migrana.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962789828P | 2019-01-08 | 2019-01-08 | |
US201962842162P | 2019-05-02 | 2019-05-02 | |
US201962872989P | 2019-07-11 | 2019-07-11 | |
PCT/US2020/012781 WO2020146527A1 (en) | 2019-01-08 | 2020-01-08 | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211707A1 true PE20211707A1 (es) | 2021-09-01 |
Family
ID=71403477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001142A PE20211707A1 (es) | 2019-01-08 | 2020-01-08 | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp |
Country Status (21)
Country | Link |
---|---|
US (4) | US11639380B2 (es) |
EP (1) | EP3908606A4 (es) |
JP (1) | JP2022516956A (es) |
KR (1) | KR20210113597A (es) |
CN (1) | CN113227140A (es) |
AU (1) | AU2020206241A1 (es) |
BR (1) | BR112020018192A2 (es) |
CA (1) | CA3123237A1 (es) |
CL (1) | CL2021001814A1 (es) |
CO (1) | CO2021008644A2 (es) |
CR (1) | CR20210373A (es) |
DO (1) | DOP2021000144A (es) |
EC (1) | ECSP21052194A (es) |
IL (1) | IL284683A (es) |
JO (1) | JOP20210156A1 (es) |
MA (1) | MA54704A (es) |
MX (1) | MX2021008267A (es) |
NI (1) | NI202100064A (es) |
PE (1) | PE20211707A1 (es) |
SG (1) | SG11202106766SA (es) |
WO (1) | WO2020146527A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3048709A1 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
TWI692485B (zh) | 2011-05-20 | 2020-05-01 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途 |
SG194974A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
MA54704A (fr) | 2019-01-08 | 2022-04-13 | H Lundbeck As | Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp |
BR112020018044A2 (pt) * | 2019-01-08 | 2021-08-10 | H. Lundbeck A/S | tratamento de dor de cabeça por uso excessivo de medicação usando anticorpos anti-cgrp ou anti-cgrp-r |
CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
EA202192865A1 (ru) * | 2019-05-02 | 2022-02-14 | Х. Лундбекк А/С | Лечение головной боли с использованием антител к cgrp |
CA3077973A1 (en) * | 2020-04-06 | 2021-10-06 | H. Lundbeck A/S | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
KR20240021800A (ko) * | 2021-05-12 | 2024-02-19 | 아납티스바이오, 아이엔씨. | 항체 조성물 |
CN117586390A (zh) * | 2022-08-11 | 2024-02-23 | 上海君实生物医药科技股份有限公司 | 抗cgrp抗体及用途 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3662333A (en) | 1970-09-08 | 1972-05-09 | Bendix Corp | Hydraulic accumulator charge detector and indicating system |
US5374618A (en) | 1983-06-15 | 1994-12-20 | Celltech Limited | Calcitonin peptides, and gene related pharmaceutical compositions |
JPS62129297A (ja) | 1985-08-09 | 1987-06-11 | Toyo Jozo Co Ltd | カルシトニン遺伝子関連ペプチド誘導体 |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
US5364841A (en) | 1988-01-11 | 1994-11-15 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and essential hypertension and related disorders |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
EP0777684B1 (en) | 1994-08-16 | 2004-04-28 | Human Genome Sciences, Inc. | Calcitonin receptor |
FR2732221B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
WO1997009046A1 (en) | 1995-09-05 | 1997-03-13 | Smithkline Beecham Corporation | Compounds and methods |
AU4261697A (en) | 1996-09-09 | 1998-03-26 | Smithkline Beecham Corporation | Compounds and methods |
JP3483893B2 (ja) | 1996-09-10 | 2004-01-06 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 |
WO1998056779A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists |
US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
WO2000018764A1 (en) | 1998-09-30 | 2000-04-06 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
AU1219000A (en) | 1998-10-22 | 2000-05-08 | Regents Of The University Of California, The | Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
US6313097B1 (en) | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
DK1259547T3 (da) | 2000-03-01 | 2012-10-15 | Medimmune Inc | Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf |
US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
US20020162125A1 (en) | 2001-03-06 | 2002-10-31 | Anne-Marie Salmon | Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal |
US20030181462A1 (en) | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
JP2005523418A (ja) | 2001-11-26 | 2005-08-04 | プロテミックス コーポレイション リミティド | 哺乳動物組織で脂質レベルを正常化するための方法及び組成物 |
US7141653B2 (en) | 2002-03-29 | 2006-11-28 | Schering Corporation | Human monoclonal antibodies to interleukin-5 |
EP1501929B1 (de) | 2002-05-06 | 2013-03-27 | Noxxon Pharma AG | Cgrp bindende nukleinsäuren |
US20040110170A1 (en) | 2002-05-18 | 2004-06-10 | The Regents Of The University Of California | Cloning and characterization of calcitonin gene related peptide receptors |
US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US20040063735A1 (en) | 2002-06-05 | 2004-04-01 | Chaturvedula Prasad V. | Calcitonin gene related peptide receptor antagonists |
CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
RS52750B (sr) | 2002-08-12 | 2013-08-30 | Birkir Sveinsson | Upotreba cgrp antagonista za lečenje psorijaze |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
CN100434440C (zh) | 2002-12-02 | 2008-11-19 | 阿布格尼克斯公司 | 针对肿瘤坏死因子的抗体及其用途 |
PT2270048E (pt) | 2002-12-24 | 2016-02-10 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
EP1605936B1 (en) | 2003-03-14 | 2011-07-20 | Merck Sharp & Dohme Corp. | Aryl spirohydantoin cgrp receptor antagonists |
ATE535514T1 (de) | 2003-03-14 | 2011-12-15 | Merck Sharp & Dohme | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten |
ATE556060T1 (de) | 2003-03-14 | 2012-05-15 | Merck Sharp & Dohme | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten |
WO2004087649A2 (en) | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
CA2519475A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin cgrp receptor antagonists |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
DE602004027021D1 (de) | 2003-04-15 | 2010-06-17 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
WO2004097421A2 (en) | 2003-04-29 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl) |
EP1644004A4 (en) | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS |
AU2004259675A1 (en) | 2003-07-15 | 2005-02-03 | Merck & Co., Inc. | Hydroxypyridine CGRP receptor antagonists |
CN101979650B (zh) | 2003-10-22 | 2015-09-16 | 凯克研究生院 | 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法 |
WO2005041757A2 (en) | 2003-10-29 | 2005-05-12 | University Of Rochester | Detection of neuropeptides associated with pelvic pain disorders and uses thereof |
EP1703915A2 (en) | 2004-01-13 | 2006-09-27 | Vasogenix Pharmaceuticals, Inc. | Methods of using cgrp for cardiovascular and renal indications |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004018794A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7279471B2 (en) | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
TWI432196B (zh) | 2005-01-18 | 2014-04-01 | Euro Celtique Sa | 內臟痛的治療 |
EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
US20100144767A1 (en) | 2005-08-25 | 2010-06-10 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
US20070108378A1 (en) | 2005-11-14 | 2007-05-17 | Toru Terabayashi | High pressure optical cell for a downhole optical fluid analyzer |
DK1957106T4 (da) | 2005-11-14 | 2019-10-28 | Teva Pharmaceuticals Int Gmbh | Antagonist-antistoffer, der er rettet mod calcitonin-gen-relateret peptid og fremgangsmåder til anvendelse af disse |
ATE493412T1 (de) | 2005-11-18 | 2011-01-15 | Merck Sharp & Dohme | Spirohydantoin-aryl-cgrp-rezeptorantagonisten |
WO2007076336A1 (en) | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
US9074352B2 (en) | 2006-03-27 | 2015-07-07 | John R. Ramun | Universal control scheme for mobile hydraulic equipment and method for achieving the same |
EP2029233A2 (en) | 2006-06-08 | 2009-03-04 | Boehringer Ingelheim International GmbH | Treatment of gastrointestinal disorders with cgrp antagonists |
AU2007275577A1 (en) | 2006-07-21 | 2008-01-24 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
HUE043782T2 (hu) | 2007-05-21 | 2019-09-30 | Alderbio Holdings Llc | IL-6 elleni antitestek és alkalmazásuk |
CA2716799C (en) | 2008-03-04 | 2018-05-22 | Pfizer Limited | Methods of treating inflammatory pain |
JP5537441B2 (ja) | 2008-03-04 | 2014-07-02 | ファイザー・リミテッド | 慢性疼痛を治療する方法 |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
CN107441487B (zh) | 2009-08-28 | 2021-09-14 | 泰华制药国际有限公司 | 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法 |
JO3330B1 (ar) | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
CA3048709A1 (en) | 2011-05-20 | 2012-11-29 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
TWI692485B (zh) | 2011-05-20 | 2020-05-01 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途 |
SG194974A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
WO2015143409A1 (en) | 2014-03-21 | 2015-09-24 | Labrys Biologics, Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
EA201890578A1 (ru) | 2015-09-24 | 2018-12-28 | Тева Фармасьютикалз Интернэшнл Гмбх | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли |
AU2017331593B2 (en) * | 2016-09-23 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
MA54704A (fr) | 2019-01-08 | 2022-04-13 | H Lundbeck As | Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp |
BR112020018044A2 (pt) | 2019-01-08 | 2021-08-10 | H. Lundbeck A/S | tratamento de dor de cabeça por uso excessivo de medicação usando anticorpos anti-cgrp ou anti-cgrp-r |
-
2020
- 2020-01-08 MA MA054704A patent/MA54704A/fr unknown
- 2020-01-08 SG SG11202106766SA patent/SG11202106766SA/en unknown
- 2020-01-08 KR KR1020217018996A patent/KR20210113597A/ko unknown
- 2020-01-08 JP JP2021539681A patent/JP2022516956A/ja active Pending
- 2020-01-08 WO PCT/US2020/012781 patent/WO2020146527A1/en active Application Filing
- 2020-01-08 PE PE2021001142A patent/PE20211707A1/es unknown
- 2020-01-08 MX MX2021008267A patent/MX2021008267A/es unknown
- 2020-01-08 AU AU2020206241A patent/AU2020206241A1/en active Pending
- 2020-01-08 EP EP20737934.8A patent/EP3908606A4/en active Pending
- 2020-01-08 CR CR20210373A patent/CR20210373A/es unknown
- 2020-01-08 JO JOP/2021/0156A patent/JOP20210156A1/ar unknown
- 2020-01-08 US US16/736,925 patent/US11639380B2/en active Active
- 2020-01-08 CA CA3123237A patent/CA3123237A1/en active Pending
- 2020-01-08 BR BR112020018192-7A patent/BR112020018192A2/pt unknown
- 2020-01-08 CN CN202080007403.2A patent/CN113227140A/zh active Pending
- 2020-02-18 US US16/793,208 patent/US11639381B2/en active Active
-
2021
- 2021-06-30 CO CONC2021/0008644A patent/CO2021008644A2/es unknown
- 2021-07-07 NI NI202100064A patent/NI202100064A/es unknown
- 2021-07-07 CL CL2021001814A patent/CL2021001814A1/es unknown
- 2021-07-07 DO DO2021000144A patent/DOP2021000144A/es unknown
- 2021-07-07 IL IL284683A patent/IL284683A/en unknown
- 2021-07-14 EC ECSENADI202152194A patent/ECSP21052194A/es unknown
-
2023
- 2023-02-23 US US18/173,124 patent/US20240067708A1/en active Pending
- 2023-02-23 US US18/173,116 patent/US20240076359A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020206241A1 (en) | 2021-08-26 |
US20240067708A1 (en) | 2024-02-29 |
US20200216524A1 (en) | 2020-07-09 |
US11639381B2 (en) | 2023-05-02 |
ECSP21052194A (es) | 2021-08-31 |
US20200299368A1 (en) | 2020-09-24 |
CR20210373A (es) | 2021-08-19 |
EP3908606A1 (en) | 2021-11-17 |
SG11202106766SA (en) | 2021-07-29 |
CO2021008644A2 (es) | 2021-07-19 |
CN113227140A (zh) | 2021-08-06 |
MX2021008267A (es) | 2021-08-05 |
IL284683A (en) | 2021-08-31 |
WO2020146527A1 (en) | 2020-07-16 |
BR112020018192A2 (pt) | 2021-08-24 |
US11639380B2 (en) | 2023-05-02 |
JOP20210156A1 (ar) | 2023-01-30 |
DOP2021000144A (es) | 2021-10-31 |
CA3123237A1 (en) | 2020-07-16 |
JP2022516956A (ja) | 2022-03-03 |
NI202100064A (es) | 2021-12-01 |
US20240076359A1 (en) | 2024-03-07 |
KR20210113597A (ko) | 2021-09-16 |
TW202039549A (zh) | 2020-11-01 |
EP3908606A4 (en) | 2022-11-23 |
CL2021001814A1 (es) | 2021-12-24 |
MA54704A (fr) | 2022-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211707A1 (es) | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp | |
PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
ES2689746T3 (es) | Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer | |
CO6190543A2 (es) | Anticuerpos anti-factor d humanizados | |
CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
CO6220978A2 (es) | Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos | |
BRPI0314814B8 (pt) | anticorpo compreendendo uma variante de fc | |
PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
PE20220708A1 (es) | Anticuerpos anti-cd73 | |
AR086984A1 (es) | Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer | |
CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
PE20230374A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
AR105541A1 (es) | ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh | |
BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
MX2021006930A (es) | Construcciones de proteínas de fusión para enfermedades asociadas al complemento. | |
PE20191743A1 (es) | Anticuerpos biespecificos anti-pd-l1-anti-tim3 | |
CR20230581A (es) | Anticuerpos anti-CCR8 y usos de los mismos | |
AU2021298632A8 (en) | Anti-CD70 antibody and application thereof | |
AR118353A1 (es) | Métodos para producir composiciones de anticuerpos anti-tnf | |
PE20230075A1 (es) | Anticuerpos anti-flt3 y composiciones | |
ZA202206670B (en) | Anti-ly6g6d antibodies and methods of use | |
WO2023004477A8 (en) | Neutralising antibodies and uses thereof | |
MX2023011919A (es) | Construcciones de proteinas de union a antigenos y anticuerpos y usos de estos. |